Great Lakes Advisors LLC Sells 12,614 Shares of Prestige Consumer Healthcare Inc. $PBH

Key Points

• Great Lakes Advisors LLC reduced its stake in Prestige Consumer Healthcare Inc. by 9.1% during the first quarter, resulting in ownership of approximately 126,502 shares worth about $10,875,000.
• Prestige Consumer Healthcare reported a net margin of 19.02% and earnings of $0.95 per share, which fell short of analysts' expectations of $1.01.
• Analyst ratings on Prestige Consumer Healthcare are mixed, with a consensus rating of "Hold" and a target price of $93.33, reflecting caution in the stock's outlook.

Great Lakes Advisors LLC lessened its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 9.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 126,502 shares of the company's stock after selling 12,614 shares during the quarter. Great Lakes Advisors LLC owned approximately 0.26% of Prestige Consumer Healthcare worth $10,875,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of PBH. Opal Wealth Advisors LLC bought a new stake in shares of Prestige Consumer Healthcare during the first quarter worth approximately $38,000. McIlrath & Eck LLC grew its position in shares of Prestige Consumer Healthcare by 19.1% in the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock valued at $75,000 after purchasing an additional 154 shares during the last quarter. Costello Asset Management INC acquired a new position in shares of Prestige Consumer Healthcare in the first quarter valued at approximately $112,000. GAMMA Investing LLC grew its position in shares of Prestige Consumer Healthcare by 35.9% in the first quarter. GAMMA Investing LLC now owns 1,879 shares of the company's stock valued at $162,000 after purchasing an additional 496 shares during the last quarter. Finally, KBC Group NV grew its position in shares of Prestige Consumer Healthcare by 7.4% in the first quarter. KBC Group NV now owns 2,199 shares of the company's stock valued at $189,000 after purchasing an additional 151 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Price Performance

NYSE PBH traded down $1.71 on Friday, hitting $63.31. 560,980 shares of the company's stock were exchanged, compared to its average volume of 562,332. The stock has a 50-day moving average of $70.53 and a 200-day moving average of $79.15. The company has a current ratio of 4.38, a quick ratio of 2.99 and a debt-to-equity ratio of 0.55. Prestige Consumer Healthcare Inc. has a 52 week low of $62.95 and a 52 week high of $90.04. The stock has a market cap of $3.12 billion, a price-to-earnings ratio of 14.86, a P/E/G ratio of 2.00 and a beta of 0.46.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing the consensus estimate of $1.01 by ($0.06). Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business had revenue of $249.53 million for the quarter, compared to the consensus estimate of $260.71 million. During the same quarter in the previous year, the company earned $0.90 earnings per share. The firm's revenue for the quarter was down 6.6% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. Analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Analysts Set New Price Targets

PBH has been the topic of several research reports. Zacks Research downgraded Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a research report on Thursday, September 4th. Wall Street Zen downgraded Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Finally, Canaccord Genuity Group cut their price target on Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $93.33.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.